Search

Your search keyword '"Pontes, Caridad"' showing total 299 results
Start Over Author "Pontes, Caridad"
299 results on '"Pontes, Caridad"'

2. Using patient-generated health data more efficient and effectively to facilitate the implementation of value-based healthcare in the EU – Innovation report

Author

Folkvord, Frans, Carlson, Jim Ingebretsen, Ottaviano, Manuel, Carvajal, Diego, Gonzalez, Liss Hernandez, van de Schoot, Rens, Turk, Eva, Piera-Jiménez, Jordi, Pontes, Caridad, Ramiro-Pareta, Marina, Carot-Sans, Gerard, Podovšovnik, Eva, Levašič, Vesna, Scheckenbach, Kathrin, Wagenmann, Martin, Szpisjak, Aron, Eliasen, Bogi, Wakim, Joe-Max, Ernst, Martin, Prinzellner, Yvonne, Bol, Nadine, He, Linwei, Krahmer, Emiel, Navarro, Clàudia, Juan, Laia, Guerri, Davide, Pinna, Laura, Genovese, Carmela, Benetti, Luciano, Macagnano, Chiara, Chiarugi, Franco, Peeters, Johannes, Pedullà, Ludovico, Brichetto, Giampaolo, Zaratin, Paola, Peschke, Seldag Gunes, Peschke, Lutz, and Fico, Giuseppe

Published
2024
Full Text
View/download PDF

5. Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use.

Author

de Pando, Thais, Grau, Santiago, Almendral, Alexander, Echeverría-Esnal, Daniel, Hernández, Sergi, Limon, Enric, and Pontes, Caridad

Abstract

Background: Lockdowns due to the COVID-19 pandemic was associated with changes in the pattern of use of antimicrobials, but persistence of changes after lockdowns has not been described. The objective was to describe the number of patients with dispensed antibiotic treatment and consumption of antibiotics in outpatients from primary care in Catalonia 18 months after the end of the emergency period. Research design and methods: Data for the COVID-19 pandemic period was obtained from March 2020 to December 2021. Four high transmission rate (Rt > 100) periods were established. To compare data, a simple Bayesian structural time series model was used. Results: The observed number of patients with dispensed antibiotics decreased respect to the estimated, especially during the four high transmission rate periods: April–May 2020 (lockdown period) (−42.57% and −42.68%); December 2020-February 2021 (−41.65%, −49.97% and −43.64%); October 2021 (−16.23%), and December 2021 (−20.16%). Overall antibiotic consumption was reduced by 23.37% (p = 0.002). These differences were mainly observed in those ≤ 15 years. Conclusions: We describe the reduction in the number of patients with dispensed antibiotics and antibiotic consumption after the COVID-19 lockdown persisted in a period of recovery of healthcare accessibility. This information may help to improve antimicrobial use at the primary care level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Author

Pontes, Caridad, Zara, Corinne, Torrent-Farnell, Josep, Obach, Merce, Nadal, Cristina, Vella-Bonanno, Patricia, Ermisch, Michael, Simoens, Steven, Hauegen, Renata Curi, Gulbinovic, Jolanta, Timoney, Angela, Martin, Antony P., Mueller, Tanja, Nachtnebel, Anna, Campbell, Stephen, Selke, Gisbert, Bochenek, Tomasz, Rothe, Celia C., Mardare, Ileana, Bennie, Marion, Fürst, Jurij, Malmstrom, Rickard E., and Godman, Brian

Published
2020
Full Text
View/download PDF

10. Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis

Author

Brunet-Mas, Eduard, primary, Garcia-Sagué, Belen, additional, Vela, Emli, additional, Melcarne, Luigi, additional, Llovet, Laura Patricia, additional, Pontes, Caridad, additional, García-Iglesias, Pilar, additional, Puy, Anna, additional, Lario, Sergio, additional, Ramirez-Lazaro, Maria Jose, additional, Villoria, Albert, additional, Burisch, Johan, additional, Kaplan, Gilaad G., additional, and Calvet, Xavier, additional

Published
2024
Full Text
View/download PDF

17. Excess mortality among older adults institutionalized in long-term care facilities during the COVID-19 pandemic: a population-based analysis in Catalonia

Author

Cases, Laia, primary, Vela, Emili, additional, Santaeugènia Gonzàlez, Sebastià J., additional, Contel, Joan Carles, additional, Carot-Sans, Gerard, additional, Coca, Marc, additional, Pastor, Marta, additional, Carrasco, Ignasi, additional, Barbeta, Conxita, additional, Vila, Anna, additional, Amil, Paloma, additional, Plaza, Aina, additional, Pontes, Caridad, additional, Piera-Jiménez, Jordi, additional, and Amblàs, Jordi, additional

Published
2023
Full Text
View/download PDF

19. Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations

Author

Valero-Bover, Damià, primary, Monterde, David, additional, Carot-Sans, Gerard, additional, Cainzos-Achirica, Miguel, additional, Comin-Colet, Josep, additional, Vela, Emili, additional, Clèries, Montse, additional, Folguera, Júlia, additional, Abilleira, Sònia, additional, Arrufat, Miquel, additional, Lejardi, Yolanda, additional, Solans, Òscar, additional, Dedeu, Toni, additional, Coca, Marc, additional, Pérez-Sust, Pol, additional, Pontes, Caridad, additional, and Piera-Jiménez, Jordi, additional

Published
2023
Full Text
View/download PDF

25. Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations

Author

Valero-Bover,DamiÃ, Monterde,David, Carot-Sans,Gerard, Cainzos-Achirica,Miguel, Comin-Colet,Josep, Vela,Emili, Clèries,Montse, Folguera,Júlia, Abilleira,Sònia, Arrufat,Miquel, Lejardi,Yolanda, Solans,Ã’scar, Dedeu,Toni, Coca,Marc, Pérez-Sust,Pol, Pontes,Caridad, Piera-Jiménez,Jordi, Valero-Bover,DamiÃ, Monterde,David, Carot-Sans,Gerard, Cainzos-Achirica,Miguel, Comin-Colet,Josep, Vela,Emili, Clèries,Montse, Folguera,Júlia, Abilleira,Sònia, Arrufat,Miquel, Lejardi,Yolanda, Solans,Ã’scar, Dedeu,Toni, Coca,Marc, Pérez-Sust,Pol, Pontes,Caridad, and Piera-Jiménez,Jordi

Abstract

Damià Valero-Bover,1,2 David Monterde,2,3 Gerard Carot-Sans,1,2 Miguel Cainzos-Achirica,4,5 Josep Comin-Colet,6– 8 Emili Vela,1,2 Montse Clèries,1,2 Júlia Folguera,1,2 Sònia Abilleira,9 Miquel Arrufat,3 Yolanda Lejardi,3 Òscar Solans,2,10 Toni Dedeu,11 Marc Coca,1,2 Pol Pérez-Sust,1 Caridad Pontes,1,2,12 Jordi Piera-Jiménez1,2,13 1Catalan Health Service, Barcelona, Spain; 2Digitalization for the Sustainability of the Healthcare System (DS3) – Institut d’Investigacions Biomèdiques de Bellvitge (IDIBELL), Barcelona, Spain; 3Catalan Institute of Health, Barcelona, Spain; 4Center for Outcomes Research, Houston Methodist, Houston, TX, USA; 5Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Medical Institutions, Baltimore, MD, USA; 6Cardiology Department, Bellvitge University Hospital (IDIBELL), Barcelona, Spain; 7Department of Medicine, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain; 8CIBER Cardiovascular (CIBERCV), L’Hospitalet de Llobregat, Barcelona, Spain; 9CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; 10Health Department, eHealth Unit, Barcelona, Spain; 11WHO European Centre for Primary Health Care, Almaty, Kazakhstan; 12Department of Pharmacology, Autonomous University of Barcelona, Barcelona, Spain; 13Faculty of Informatics, Telecommunications and Multimedia, Universitat Oberta de Catalunya, Barcelona, SpainCorrespondence: Jordi Piera-Jiménez, Catalan Health Service, Gran Via de les Corts Catalanes 587, Barcelona, 08007, Spain, Tel +34 93 403 85 85, Email jpiera@catsalut.catPurpose: To assess the contribution of age and comorbidity to the risk of critical illness in hospitalized COVID-19 patients using increasingly exhaustive tools for measuring comorbidity burden.Patients and Methods: We assessed the effect of age and comorbidity burden in a retrospective, multicenter cohort of patients hospitalized due to COVID-19 in Catalonia (North-East Spain) between March 1, 2

Published
2023

27. Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Author

Godman, Brian, primary, Wladysiuk, Magdalene, additional, McTaggart, Stuart, additional, Kurdi, Amanj, additional, Allocati, Eleonora, additional, Jakovljevic, Mihajlo, additional, Kalemeera, Francis, additional, Hoxha, Iris, additional, Nachtnebel, Anna, additional, Sauermann, Robert, additional, Hinteregger, Manfred, additional, Marković-Peković, Vanda, additional, Tubic, Biljana, additional, Petrova, Guenka, additional, Tachkov, Konstantin, additional, Slabý, Juraj, additional, Nejezchlebova, Radka, additional, Krulichová, Iva Selke, additional, Laius, Ott, additional, Selke, Gisbert, additional, Langner, Irene, additional, Harsanyi, András, additional, Inotai, András, additional, Jakupi, Arianit, additional, Henkuzens, Svens, additional, Garuolienė, Kristina, additional, Gulbinovič, Jolanta, additional, Bonanno, Patricia Vella, additional, Rutkowski, Jakub, additional, Ingeberg, Skule, additional, Melien, Øyvind, additional, Mardare, Ileana, additional, Fürst, Jurij, additional, MacBride-Stewart, Sean, additional, Holmes, Carol, additional, Pontes, Caridad, additional, Zara, Corinne, additional, Pedrola, Marta Turu, additional, Hoffmann, Mikael, additional, Kourafalos, Vasileios, additional, Pisana, Alice, additional, Banzi, Rita, additional, Campbell, Stephen, additional, and Wettermark, Bjorn, additional

Published
2023
Full Text
View/download PDF

37. Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study

Author

Selke Krulichová, Iva, primary, Selke, Gisbert W., additional, Bennie, Marion, additional, Hajiebrahimi, Mohammadhossein, additional, Nyberg, Fredrik, additional, Fürst, Jurij, additional, Garuolienė, Kristina, additional, Poluzzi, Elisabetta, additional, Slabý, Juraj, additional, Yahni, Corinne Zara, additional, Altini, Mattia, additional, Fantini, Maria Pia, additional, Kočí, Václav, additional, McTaggart, Stuart, additional, Pontes, Caridad, additional, Reno, Chiara, additional, Rosa, Simona, additional, Pedrola, Marta Turu, additional, Udovič, Mitja, additional, and Wettermark, Björn, additional

Published
2022
Full Text
View/download PDF

38. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

Author

Pisana, Alice, primary, Wettermark, Björn, additional, Kurdi, Amanj, additional, Tubic, Biljana, additional, Pontes, Caridad, additional, Zara, Corinne, additional, Van Ganse, Eric, additional, Petrova, Guenka, additional, Mardare, Ileana, additional, Fürst, Jurij, additional, Roig-Izquierdo, Marta, additional, Melien, Oyvind, additional, Bonanno, Patricia Vella, additional, Banzi, Rita, additional, Marković-Peković, Vanda, additional, Mitkova, Zornitsa, additional, and Godman, Brian, additional

Published
2022
Full Text
View/download PDF

40. Heterogeneity in pharmacological treatment and outcomes in Crohn’s disease patients in Catalonia: a population-based observational study

Author

Brunet, Eduard, primary, Vela, Emili, additional, Melcarne, Luigi, additional, Llovet, Laura-Patricia, additional, Puy, Anna, additional, Clèries, Montserrat, additional, Pontes, Caridad, additional, García-Iglesias, Pilar, additional, Villòria, Albert, additional, Kaplan, Gilaad G., additional, and Calvet, Xavier, additional

Published
2022
Full Text
View/download PDF

41. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis

Author

Vinson, Dorothee, Molet-Benhamou, L., Degboé, Y., den Broeder, A., Ibrahim, F., Pontes, Caridad, Westhovens, R., Závada, J., Pham, T., Barnetche, T., Constantin, Arnaud, Ruyssen-Witrand, A., Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Sint Maartenskliniek, King‘s College London, Universitat Autònoma de Barcelona (UAB), University Hospitals Leuven [Leuven], Charles University [Prague] (CU), Groupe hospitalier Pellegrin, CHU de Bordeaux Pellegrin [Bordeaux], and PINIER, CHRISTINE

Subjects
Viruses infection, lcsh:Diseases of the musculoskeletal system, DISEASE-ACTIVITY, DMARDs, Arthritis, Rheumatoid, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030212 general & internal medicine, Incidence (epidemiology), Absolute risk reduction, ANKYLOSING-SPONDYLITIS, OPEN-LABEL, 3. Good health, Infection bacteria, Antirheumatic Agents, Rheumatoid arthritis, Meta-analysis, NON-INFERIORITY, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Life Sciences & Biomedicine, Research Article, medicine.medical_specialty, Subgroup analysis, CERTOLIZUMAB PEGOL, 03 medical and health sciences, Rheumatology, Internal medicine, SCORE, Spondylarthritis, Spondyloarthritis, ETANERCEPT, medicine, Humans, Adverse effect, Janus Kinases, 030203 arthritis & rheumatology, Biological Products, Science & Technology, DOSE REDUCTION, business.industry, REMISSION, medicine.disease, Confidence interval, MAINTENANCE, Systematic review, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Tumor Necrosis Factor Inhibitors, Controlled Clinical Trials as Topic, Biological therapies, lcsh:RC925-935, business
Abstract

Objectives To systematically review the impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and severe adverse events (SAEs) in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) in remission or low disease activity (LDA) state. Materials and methods A meta-analysis based on a systematic review of PubMed, Embase, Cochrane, until August 2019, as well as relevant databases of international conferences, was used to evaluate the risk difference (RD) at 95% confidence interval (95% CI) of incidence density of serious infections, SAEs, malignancies, cardiovascular adverse events (CV AEs), or deaths after tapering (dose reduction or spacing) compared to continuation of targeted therapies. Results Of the 1957 studies initially identified, 13 controlled trials (9 RA and 4 SpA trials) were included in the meta-analysis. 1174 patient-years were studied in the tapering group (TG) versus 1086 in the usual care group (UC). There were 1.7/100 patient-year (p-y) serious infections in TG versus 2.6/100 p-y in UC (RD (95% CI) 0.01 (0.00 to 0.02), p = 0.13) and 7.4/100 p-y SAEs in TG versus 6.7/100 p-y in UC (RD 0.00 (− 0.02 to 0.02), p = 0.82). The risk of malignancies, CV AEs, or deaths did not differ between the tapering and the usual care groups. Subgroup analysis (RA and SpA) detected no significant differences between the two groups. Conclusion We could not show significant impact of tapering bDMARD or JAKi over continuation concerning the risk of serious infections, SAEs, malignancies, CV AEs, or deaths in RA and SpA patients in remission or LDA state.

Published
2020
Full Text
View/download PDF

42. Biosimilars are essential for sustainable healthcare systems across Europe; however, key challenges remain as seen with biosimilars for long-acting insulin analogues

Author

Godman, Brian, Tubić, Biljana, Allocati, Eleonora, Wladysiuk, Magdalene, McTaggart, Stuart, Kurdi, Amanj, Haque, Mainul, MacBride-Stewart, Sean, Kalemeera, Francis, Massele, Amos, Hoxha, Iris, Marković-Peković, Vanda, Petrova, Guenka, Tachkov, Konstantin, Laius, Ott, Harsanyi, András, Inotai, Andras, Jakupi, Arianit, Henkuzens, Svens, Garuolienė, Kristina, Vella Bonanno, Patricia, Rutkowski, Jakub, Mardare, Ileana, Fürst, Jurij, Pontes, Caridad, Zara, Corinne, Turu Pedrola, Marta, Akter, Farhana, Kwon, Hye-Young, Martin, Antony P, Banzi, Rita, Wale, Janney, and Gulbinovic, Jolanta

Subjects
RS
Abstract

Sales of medicines continue to grow world-wide driven in part by increasing expenditures on biological medicines leading to concerns with the long-term sustainability of European healthcare systems. The increasing use of biosimilars at lower costs can potentially address this. However, there can be concerns with their prescribing. There are also concerns with biosimilar insulin glargine including concerns with different devices despite increasing sales of long-acting insulin analogues worldwide. Consequently, a need to appraise the European biosimilar market incorporating measures to enhance their use including potential ways to increase the prescribing of biosimilars of insulin glargine at lower costs. Multiple approaches were used to undertake the study including measures to enhance biosimilar use and their impact across Europe. In addition, undertake cross national research on the utilization and expenditure of long-acting insulin analogues, which includes biosimilars, principally among Central and Eastern European countries. Multiple demand-side measures across countries have enhanced the use of biosimilars. There was variable use of biosimilar insulin glargine 100IU/ml driven by increasing use of patented 300IU/ml formulations and small price differences between the originator and biosimilars in practice. Overall, multiple demand-side initiatives can appreciably increase biosimilar use benefiting all groups. Additional measures are needed to enhance future prescribing of long-acting biosimilar insulin analogues.

Published
2022

43. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

Author

Pisana, Alice, Wettermark, Björn, Kurdi, Amanj, Tubic, Biljana, Pontes, Caridad, Zara, Corinne, Van Ganse, Eric, Petrova, Guenka, Mardare, Ileana, Fürst, Jurij, Roig-Izquierdo, Marta, Melien, Oyvind, Bonanno, Patricia Vella, Banzi, Rita, Markovic-Pekovic, Vanda, Mitkova, Zornitsa, Godman, Brian, Pisana, Alice, Wettermark, Björn, Kurdi, Amanj, Tubic, Biljana, Pontes, Caridad, Zara, Corinne, Van Ganse, Eric, Petrova, Guenka, Mardare, Ileana, Fürst, Jurij, Roig-Izquierdo, Marta, Melien, Oyvind, Bonanno, Patricia Vella, Banzi, Rita, Markovic-Pekovic, Vanda, Mitkova, Zornitsa, and Godman, Brian

Abstract

Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluation generates uncertainty over their cost-effectiveness and increases expenditure for unknown health gain. Patient-level data can complement clinical trials and generate better evidence on the effectiveness, safety and outcomes of these new medicines in routine care. This can support policy decisions including funding. Consequently, there is a need for improving datasets for establishing real-world outcomes of newly launched oncology medicines.Aim: To outline the types of available datasets for collecting patient-level data for oncology among different European countries. Additionally, to highlight concerns regarding the use and availability of such data from a health authority perspective as well as possibilities for cross-national collaboration to improve data collection and inform decision-making.Methods: A mixed methods approach was undertaken through a cross-sectional questionnaire followed-up by a focus group discussion. Participants were selected by purposive sampling to represent stakeholders across different European countries and healthcare settings. Descriptive statistics were used to analyze quantifiable questions, whilst content analysis was employed for open-ended questions.Results: 25 respondents across 18 European countries provided their insights on the types of datasets collecting oncology data, including hospital records, cancer, prescription and medicine registers. The most available is expenditure data whilst data concerning effectiveness, safety and outcomes is less available, and there are concerns with data validity. A major constraint to data collection is the lack of comprehensive registries and limited data on effectiveness, safety and outcomes of new medicines. Data ownership limits data access

Published
2022
Full Text
View/download PDF

44. Comparison of drug prescribing before and during the COVID-19 pandemic : A cross-national European study

Author

Krulichova, Iva Selke, Selke, Gisbert W., Bennie, Marion, Hajiebrahimi, Mohammadhossein, Nyberg, Fredrik, Furst, Jurij, Garuoliene, Kristina, Poluzzi, Elisabetta, Slaby, Juraj, Zara Yahni, Corinne, Altini, Mattia, Fantini, Maria Pia, Koci, Vaclav, McTaggart, Stuart, Pontes, Caridad, Reno, Chiara, Rosa, Simona, Turu Pedrola, Marta, Udovic, Mitja, Wettermark, Björn, Krulichova, Iva Selke, Selke, Gisbert W., Bennie, Marion, Hajiebrahimi, Mohammadhossein, Nyberg, Fredrik, Furst, Jurij, Garuoliene, Kristina, Poluzzi, Elisabetta, Slaby, Juraj, Zara Yahni, Corinne, Altini, Mattia, Fantini, Maria Pia, Koci, Vaclav, McTaggart, Stuart, Pontes, Caridad, Reno, Chiara, Rosa, Simona, Turu Pedrola, Marta, Udovic, Mitja, and Wettermark, Björn

Abstract

Purpose The COVID-19 pandemic had an impact on health care, with disruption to routine clinical care. Our aim was to describe changes in prescription drugs dispensing in the primary and outpatient sectors during the first year of the pandemic across Europe. Methods We used routine administrative data on dispensed medicines in eight European countries (five whole countries, three represented by one region each) from January 2017 to March 2021 to compare the first year of the COVID-19 pandemic with the preceding 3 years. Results In the 10 therapeutic subgroups with the highest dispensed volumes across all countries/regions the relative changes between the COVID-19 period and the year before were mostly of a magnitude similar to changes between previous periods. However, for drugs for obstructive airway diseases the changes in the COVID-19 period were stronger in several countries/regions. In all countries/regions a decrease in dispensed DDDs of antibiotics for systemic use (from -39.4% in Romagna to -14.2% in Scotland) and nasal preparations (from -34.4% in Lithuania to -5.7% in Sweden) was observed. We observed a stockpiling effect in the total market in March 2020 in six countries/regions. In Czechia the observed increase was not significant and in Slovenia volumes increased only after the end of the first lockdown. We found an increase in average therapeutic quantity per pack dispensed, which, however, exceeded 5% only in Slovenia, Germany, and Czechia. Conclusions The findings from this first European cross-national comparison show a substantial decrease in dispensed volumes of antibiotics for systemic use in all countries/regions. The results also indicate that the provision of medicines for common chronic conditions was mostly resilient to challenges faced during the pandemic. However, there were notable differences between the countries/regions for some therapeutic areas.

Published
2022
Full Text
View/download PDF

46. Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues

Author

Godman Brian, Tubic Biljana, Allocati Eleonora, Wladysiuk Magdalene, McTaggart Stuart, Kurdi Amanj, Haque Mainul, MacBride-Stewart Sean, Kalemeera Francis, Massele Amos, Hoxha Iris, Pekovic Vanda Markovic, Petrova Guenka, Tachkov Konstantin, Laius Ott, Harsanyi András, Inotai András, Jakupi Arianit, Henkuzens Svens, Garuoliené Kristina, Bonanno Patricia Vella, Rutkowski Jakub, Mardare Ileana, Fürst Jurij, Pontes Caridad, Zara Corinne, Pedrola Marta Turu, Akter Farhana, Kwon Hye-Young, Martin Antony P., Banzi Rita, Wale Janney, and Gulbinovic Jolanta

Subjects
Drug monitoring -- Europe, Biosimilar pharmaceuticals -- Europe, Drugs -- Prescribing -- Economic aspects, Insulin -- Costs, Drug accessibility -- Law and legislation -- Europe, Biosimilars, Demand-side measures, Europe, Health policies, Insulin glargine, Prices, Medicine (miscellaneous), Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics
Abstract

Sales of medicines continue to grow world-wide driven in part by increasing expenditures on biological medicines leading to concerns with the long-term sustainability of European healthcare systems. The increasing use of biosimilars at lower costs can potentially address this. However, there can be concerns with their prescribing. There are also concerns with biosimilar insulin glargine including concerns with different devices despite increasing sales of longacting insulin analogues worldwide. Consequently, a need to appraise the European biosimilar market incorporating measures to enhance their use including potential ways to increase the prescribing of biosimilars of insulin glargine at lower costs. Multiple approaches were used to undertake the study including researching measures to enhance biosimilar use and their impact across Europe. In addition, undertake cross national research on the utilization and expenditure of long-acting insulin analogues, which includes biosimilars, principally among Central and Eastern European countries. Multiple demand-side measures across the countries have enhanced the use of biosimilars. There was variable use of biosimilar insulin glargine 100 IU/ml driven by increasing use of patented 300 IU/ml formulations and small price differences between the originator and biosimilars in practice. Overall, multiple demand-side initiatives can appreciably increase biosimilar use benefiting all groups. Additional measures are needed to enhance future prescribing of long-acting biosimilar insulin analogues., peer-reviewed

Published
2022

47. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

Author

Godman, Brian, primary, Wladysiuk, Magdalene, additional, McTaggart, Stuart, additional, Kurdi, Amanj, additional, Allocati, Eleonora, additional, Jakovljevic, Mihajlo, additional, Kalemeera, Francis, additional, Hoxha, Iris, additional, Nachtnebel, Anna, additional, Sauermann, Robert, additional, Hinteregger, Manfred, additional, Marković-Peković, Vanda, additional, Tubic, Biljana, additional, Petrova, Guenka, additional, Tachkov, Konstantin, additional, Slabý, Juraj, additional, Nejezchlebova, Radka, additional, Krulichová, Iva Selke, additional, Laius, Ott, additional, Selke, Gisbert, additional, Langner, Irene, additional, Harsanyi, András, additional, Inotai, András, additional, Jakupi, Arianit, additional, Henkuzens, Svens, additional, Garuolienė, Kristina, additional, Gulbinovič, Jolanta, additional, Bonanno, Patricia Vella, additional, Rutkowski, Jakub, additional, Ingeberg, Skule, additional, Melien, Øyvind, additional, Mardare, Ileana, additional, Fürst, Jurij, additional, MacBride-Stewart, Sean, additional, Holmes, Carol, additional, Pontes, Caridad, additional, Zara, Corinne, additional, Pedrola, Marta Turu, additional, Hoffmann, Mikael, additional, Kourafalos, Vasileios, additional, Pisana, Alice, additional, Banzi, Rita, additional, Campbell, Stephen, additional, and Wettermark, Bjorn, additional

Published
2021
Full Text
View/download PDF

48. Variation in the prices of oncology medicines across Europe and the implications for the future

Author

Godman, Brian, primary, Simoens, Steven, additional, Kurdi, Amanj, additional, Selke, Gisbert, additional, Yfantopoulos, John, additional, Hill, Andrew, additional, Gulbinovic, Jolanta, additional, Martin, Antony P, additional, Timoney, Angela, additional, Gotham, Dzintars, additional, Wale, Janet, additional, Bochenek, Tomasz, additional, Selke Krulichova, Iva, additional, Allocati, Eleonora, additional, Hoxha, Iris, additional, Malaj, Admir, additional, Nachtnebel, Anna, additional, Hamelinck, Wouter, additional, Mitkova, Zornitza, additional, Petrova, Guenka, additional, Laius, Ott, additional, Sermet, Catherine, additional, Langner, Irene, additional, Joppi, Roberta, additional, Jakupi, Arianit, additional, Poplavska, Elita, additional, Greiciute-Kuprijanov, Ieva, additional, Vella Bonanno, Patricia, additional, Piepenbrink, JF Hans, additional, de Valk, Vincent, additional, Plisko, Robert, additional, Wladysiuk, Magdalene, additional, Markovic-Pekovic, Vanda, additional, Mardare, Ileana, additional, Novakovic, Tanja, additional, Parker, Mark, additional, Furst, Jurij, additional, Tomek, Dominik, additional, Banasova, Katarina, additional, Obach Cortadellas, Merce, additional, Zara, Corrine, additional, Pontes, Caridad, additional, Juhasz-Haverinen, Maria, additional, Skiold, Peter, additional, McTaggart, Stuart, additional, Wong-Rieger, Durhane, additional, Campbell, Stephen, additional, and Hill, Ruaraidh, additional

Published
2021
Full Text
View/download PDF

49. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe : Findings and Implications

Author

Godman, Brian, Wladysiuk, Magdalene, McTaggart, Stuart, Kurdi, Amanj, Allocati, Eleonora, Jakovljevic, Mihajlo, Kalemeera, Francis, Hoxha, Iris, Nachtnebel, Anna, Sauermann, Robert, Hinteregger, Manfred, Marković-Peković, Vanda, Tubic, Biljana, Petrova, Guenka, Tachkov, Konstantin, Slabý, Juraj, Nejezchlebova, Radka, Krulichová, Iva Selke, Laius, Ott, Selke, Gisbert, Langner, Irene, Harsanyi, András, Inotai, András, Jakupi, Arianit, Henkuzens, Svens, Garuolienė, Kristina, Gulbinovič, Jolanta, Bonanno, Patricia Vella, Rutkowski, Jakub, Ingeberg, Skule, Melien, Øyvind, Mardare, Ileana, Fürst, Jurij, MacBride-Stewart, Sean, Holmes, Carol, Pontes, Caridad, Zara, Corinne, Pedrola, Marta Turu, Hoffmann, Mikael, Kourafalos, Vasileios, Pisana, Alice, Banzi, Rita, Campbell, Stephen, Wettermark, Björn, Godman, Brian, Wladysiuk, Magdalene, McTaggart, Stuart, Kurdi, Amanj, Allocati, Eleonora, Jakovljevic, Mihajlo, Kalemeera, Francis, Hoxha, Iris, Nachtnebel, Anna, Sauermann, Robert, Hinteregger, Manfred, Marković-Peković, Vanda, Tubic, Biljana, Petrova, Guenka, Tachkov, Konstantin, Slabý, Juraj, Nejezchlebova, Radka, Krulichová, Iva Selke, Laius, Ott, Selke, Gisbert, Langner, Irene, Harsanyi, András, Inotai, András, Jakupi, Arianit, Henkuzens, Svens, Garuolienė, Kristina, Gulbinovič, Jolanta, Bonanno, Patricia Vella, Rutkowski, Jakub, Ingeberg, Skule, Melien, Øyvind, Mardare, Ileana, Fürst, Jurij, MacBride-Stewart, Sean, Holmes, Carol, Pontes, Caridad, Zara, Corinne, Pedrola, Marta Turu, Hoffmann, Mikael, Kourafalos, Vasileios, Pisana, Alice, Banzi, Rita, Campbell, Stephen, and Wettermark, Björn

Abstract

Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results. Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder g, Correction in: Biomed Research International, Volume 2023 | Article ID 9757348DOI: 10.1155/2023/9757348

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results